AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

JUNS · NASDAQ · Biotechnology

Jupiter Neurosciences

Develops CNS drug candidates and sells Nugevia longevity supplements.

$3.07

After-hours close−1.09 (−26.11%)

At close$4.16(−15.03%)

Something off on this page? Send us feedback.

Profile

Jupiter Neurosciences, Inc.JUNSHealth Care

Develops investigational CNS medicines around a micellar-resveratrol platform and sells Nugevia nutritional supplements online. Revenue currently comes from supplements, while drug commercialization depends on clinical progress, regulatory approval, and licensed Aquanova technology.

Develops CNS drug candidates around JOTROL, a micellar resveratrol formulation used in JNS115, an exploratory Parkinson's study, while holding U.S. rights to the separate ALA-002 MDMA-based candidate. Potential follow-on JOTROL programs include mild cognitive impairment, early Alzheimer's disease and several rare diseases.

Also sells Nugevia supplements—GLO, MND and PWR—through U.S. direct-to-consumer e-commerce. Liquid ingredients are prepared by Aquanova in Germany, then encapsulated in California and shipped to consumers; European, Middle Eastern and Southeast Asian expansion remains planned.

Operates primarily as a virtual organization, with a small internal team coordinating strategy and regulatory work while outside partners conduct much of R&D, clinical operations and manufacturing. No drug candidate has FDA marketing approval, and both business segments depend on Aquanova's exclusive license, formulation technology and initial manufacturing step.

Company facts

CEOChrister Rosén

ListedDec 3, 2024

ExchangeNASDAQ

HeadquartersPalm Beach Gardens, FL

CountryUnited States

Employees5

CIK0001679628

ISINUS48208B3024

Key statistics

Market cap$2.0M

EPS (ttm)−$19.33

P/E (ttm)−0.2162

ROE747.3%

P/B−6.37

P/S31.32

Dividend yield—

Beta1.74vs XLV 0.61

Year to date −94.5% · Average volume (30d) 2.0M

Analysts

No analyst consensus on record.

Earnings

EPS

Estimate−$3.75

Reported−$5.06−34.9%

Revenue

Estimate$400.0K

Reported$24.2K−93.9%

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 14, 2026Q2 FY26	−$3.75	−$5.06	−34.9%	$400.0K	$24.2K	−93.9%	−12.67%
May 21, 2026Q1 FY26	−$3.75	−$4.39	−17.0%	$400.0K	$18.7K	−95.3%	−12.16%
May 14, 2026Q1 FY26	−$0.05	−$0.06	−20.0%	$225.0K	$18.7K	−91.7%	−3.28%
Apr 3, 2026Q4 FY25	−$5.25	−$5.61	−6.9%	$75.0K	$21.8K	−70.9%	−7.49%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$0	$21.8K	$18.7K	$24.2K
Gross profit	$0	$0	$0	$21.8K	$14.3K	$21.1K
Operating income	−$1.5M	−$2.3M	−$2.3M	−$2.8M	−$2.0M	−$2.7M
Net income	−$1.5M	−$2.3M	−$2.3M	−$2.6M	−$2.1M	−$2.3M
Diluted EPS	−$3.47	−$5.09	−$5.25	−$5.61	−$4.39	−$4.08
Gross margin	—	—	—	100.0%	76.6%	86.9%
Operating margin	—	—	—	-12,886.7%	-10,524.3%	-11,313.4%

Fiscal years (4-quarter sums)FY21 $638.0K · FY23 $0 · FY24 $0 · FY25 $21.8K

Balance sheet, Jun 30, 2026Cash & short-term investments $1.5M · Total debt $1.7M · Total assets $3.7M · Shareholders' equity −$366.0K

Dividends

No dividends on record.

Ownership

Institutions 5.24%25.4K sharesInsiders 41.39%200.6K sharesOther 53.37%258.7K shares

Shares outstanding 484.7K · Float 221.2K · 45.7% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Orca Capital AG	102.6K	8.40%	13G	Aug 28, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.